Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Aligos Therapeutics reported significant progress in Q2 2026, including completing enrollment for its Phase 2 study of pevifoscorvir sodium for chronic HBV infection and receiving key regulatory designations such as Breakthrough Therapy in China and Fast Track in the US. The company secured $25 million upfront from an exclusive Greater China licens…
Zscaler, Inc., a leading cybersecurity platform, will release its fourth quarter fiscal year 2026 earnings after market close on September 3, 2026, followed by an investor conference call to discuss the results.
Black Rock Coffee Bar is continuing its robust expansion in the Valley by opening a new location in Tempe, Arizona, increasing its Arizona footprint to 60 stores. The company promotes its handcrafted specialty beverages and recently added food items while leveraging its loyalty rewards app to enhance customer engagement.
MIRA Pharmaceuticals announced positive toxicokinetic data from a 7-day repeated-dose study of their obesity treatment candidate SKNY-1 in Beagle dogs. The drug showed dose-dependent systemic exposure and rapid absorption, de-risking dose selection and supporting advancement into GLP toxicology studies and IND-enabling development. SKNY-1 aims to t…
Exyn Technologies announced that its Exyn Nexys handheld LiDAR scanner has been chosen by a leading U.S. government research and engineering organization following a rigorous head-to-head assessment against other commercial LiDAR systems. The device was selected due to its survey-grade accuracy, mobility, and speed, and will be used for creating de…
Prime Medicine reported Q2 2026 financial results highlighting progress in its gene editing pipeline including the initiation of a global Phase 1/2 trial for PM577a targeting Wilson disease, regulatory clearances in the US and New Zealand, and a favorable arbitration outcome securing rights to PM647 for Alpha-1 Antitrypsin Deficiency. The FDA grant…
Tejon Ranch Co. announced its second quarter 2026 financial results, reporting net income attributable to common stockholders increased by $4.3 million to $2.6 million compared to a loss in the prior year. Revenues rose $6.3 million to $17.4 million driven by land sales and growth in multifamily, mineral resources, and ranch operations segments. Th…
LENSAR, Inc., a US-based medical technology company specializing in robotic laser solutions for cataract treatment, will release its second quarter 2026 financial results before market open on August 13, 2026. The company will host a conference call and webcast to discuss results, corporate highlights, and strategic initiatives.
X-energy, a developer of advanced small modular reactors, has entered a long-term agreement with Centrus Energy to supply enriched HALEU fuel critical for the Xe-100 reactor projects. This partnership de-risks X-energy's 11.5 GW commercial pipeline by securing a domestic, stable supply of HALEU and advances U.S. nuclear fuel commercialization, supp…
Clearmind Medicine announced that its Independent Data and Safety Monitoring Board (DSMB) has unanimously approved progressing its FDA-regulated Phase I/II clinical trial of CMND-100 in patients with Alcohol Use Disorder (AUD). Following a successful safety evaluation in healthy participants, the study will now advance to Parts B and C, including t…
Vivani Medical announced full enrollment and successful dosing of all 20 participants in its Phase 1 SLIM-1 trial evaluating NPM-139, a miniature subdermal semaglutide implant designed for ultra long-acting delivery over 6 to 12 months. The trial is assessing safety, tolerability, and pharmacokinetics compared to Wegovy injections, with topline dat…
Genius Group Limited (NYSE: GNS) announced the launch of the first phase of its $14 million Genius City joint venture in Nuanu Creative City, Bali, Indonesia. The project includes Genius Zone, Genius Café, Genius Missions, and Genius School, which opened with a record enrollment of 235 students and strong growth projections. Genius City aims to est…
Aemetis, Inc. announced strong financial results for Q2 2026 with revenues increasing 20% year-over-year to $62.7 million driven by growth in California Ethanol and Dairy Renewable Natural Gas segments. The company reported positive operating income of $5.8 million, a turnaround from an operating loss in the prior year period, supported by $8.6 mil…
Merlin, Inc. has successfully reached the Stage of Involvement 3 (SOI 3) milestone with the Civil Aviation Authority of New Zealand for key components of its autonomous flight system. This accomplishment advances Merlin's certification process, demonstrating the safety and reliability of their aviation-grade autonomous flight technology. The compan…
SHF Holdings, Inc. (Safe Harbor) announced that Canopy HR has selected Safe Harbor's Multiple Employer 401(k) Plan as the recommended retirement solution for its cannabis industry clients. Since its launch in April 2026, the plan has onboarded six new cannabis businesses, including a multistate operator, demonstrating strong early market adoption. …
Corbus Pharmaceuticals Holdings, Inc. reported Q2 2026 financial results and provided a corporate update highlighting FDA clearance to proceed with the registrational TEMPO-1 Phase 3 trial for CRB-701 in oropharyngeal cancer, and upcoming data from the CANYON-1 Phase 1b study of CRB-913 for obesity. The company also announced key senior leadership …
ALX Oncology reported second quarter 2026 financial results, highlighted advancements in clinical trials for its oncology therapies evorpacept and ALX2004, reinforced its leadership team, and secured a new debt facility. The company remains on track for topline data from its Phase 2 breast cancer trial in mid-2027 and expects initial safety data fr…
Theriva Biologics has dosed the first patient in its VIRAGE2 Phase 2a trial, aiming to evaluate more frequent dosing of its oncolytic virus therapy, VCN-01, in combination with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). Building upon encouraging Phase 2b data, this exploratory study seeks to refine dosing regimens…
Ascendis Pharma announced positive data from its Phase 2 COACH trial combining TransCon CNP and TransCon hGH, showing sustained, unprecedented growth in children with achondroplasia through Week 78. Additionally, the pivotal ApproaCH trial demonstrated durable benefits from TransCon CNP monotherapy over two years. The company also reported signific…
Belite Bio announced a webcast to discuss its second quarter 2026 financial results and business update, focusing on its clinical-stage drug development targeting degenerative retinal diseases. The company is advancing trials for its lead candidate tinlarebant, intended to treat Stargardt disease type 1 and geographic atrophy in age-related macular…
MNTN looks set to trade higher as operating cash flow catches up with earnings and the company's net-cash balance sheet separates enterprise value from headline market cap. Premium multiples still price growth, but a clear path to stronger free cash generation and several near-term catalysts create a pragmatic trade: enter at $10.30, target $14.00,…
Acorn Energy announced its Q2 2026 results, highlighting a 29% revenue decline primarily due to lower hardware sales from a major cell phone provider contract. However, high-margin recurring monitoring revenue grew 8% and gross margins improved significantly. Growth initiatives include a strategic partnership with Champion Power Equipment for resid…
ConocoPhillips completed a $1.7 billion sale of noncore Lower 48 assets in July, allowing the company to achieve its $5 billion divestiture target earlier than planned. The transaction was disclosed alongside second-quarter results that showed better-than-expected profit, and coincided with the announcement that CEO Ryan Lance will retire and CFO A…
Datadog shares tumbled roughly 21% in premarket trading to around $223 despite a quarter that beat expectations across revenue and earnings and lifted full-year guidance. The company reported $1.12 billion in revenue, up 36% year-over-year, and raised its revenue and EPS targets for the year. Investors appear to be reacting to a long run-up into th…
Keurig Dr Pepper shares rose about 1% in pre-market trading after the company reported adjusted earnings of $0.57 per share and net sales of $7.31 billion for the second quarter, both ahead of consensus. The results reflect substantial year-over-year revenue growth driven in part by the April 2026 closing of the $18 billion JDE Peet’s acquisition. …
